Please login to the form below

Not currently logged in
Email:
Password:

Amgen buoyant as profits rise in Q3

Increases 2012 revenue and earnings forecasts

Amgen

Amgen has boosted its 2012 revenue and earnings forecasts after posting a double-digit sales increase in the third quarter driven by arthritis drug Enbrel.

Operating income came in at $1.7bn in the quarter, a rise of 14 per cent and topping analyst estimates, while revenues climbed 10 per cent to $4.32bn, giving new chief executive Robert Bradway a great start in his first full-quarter at the helm.

"Our business has very good momentum, and we're executing on our strategy to grow the business and deliver for patients and shareholders," said Bradway on a conference call to discuss the figures.

Amgen's biggest product franchise - the white cell stimulators Neulasta (pegfilgrastim) and Neupogen (filgrastim) - held up well despite their advancing years and recording $1.34bn in third-quarter sales thanks to direct-to-consumer (DTC) and caregiver advertising.

Among Amgen's growth products, sales of Enbrel (etanercept) grew 17 per cent to $1.08bn while Xgeva (denosumab) for bone fracture prevention climbed 12 per cent to $201m.

Hyperparathyroidism drug Sensipar/Mimpara (cinacalcet) had a good quarter, up 18 per cent to $243m, while colorectal cancer drug Vectibix (panitumumab) rose 11 per cent to $88m. Nplate (romiplostim) for the treatment of chronic immune thrombocytopenic purpura climbed 18 per cent to $91m.

On the downside, Amgen's red blood cell stimulator Aranesp (darbepoetin alfa) fell 17 per cent to $497m as a result of changing practice patterns, competition in oncology and safety issues.

However, Amgen's older drug in this category – Epogen (epoetin alfa) – managed a 3 per cent gain to $491m thanks to lower-than-expected competition and resistance by dialysis providers to switch to newer drugs such as Takeda/Affymax' Omontys (peginasetide), which was approved in the US earlier this year.

"We now expect full year revenues to fall between $17.2bn and $17.3bn," said chief financial officer Jonathon Peacock, adding that earnings per share (EPS) will be in the $6.50-$6.60 range.

Amgen was previously predicting revenues of $16.9-$17.2bn in revenues and EPS of $6.20-$6.35.

Looking to 2013, Amgen expects R&D costs to rise as it ramps up phase III trials for romosozumab, a monoclonal antibody for the treatment of postmenopausal osteoporosis, and starts preparing for pivotal trials of cholesterol-lowering therapy AMG 145.

24th October 2012

From: Sales

Share

Tags



Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Seven Stones

Seven Stones is a creative, independent healthcare communications agency focused on great work with a strong and effective ‘Media Neutral’...

Latest intelligence

England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....
Pharma deal watch - handshake
Pharma deals during March 2014
Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month...